Erschienen in:
11.03.2017 | Multiple Myeloma (P Kapoor, Section Editor)
Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work
verfasst von:
Qaiser Bashir, Muzaffar H. Qazilbash
Erschienen in:
Current Hematologic Malignancy Reports
|
Ausgabe 2/2017
Einloggen, um Zugang zu erhalten
Abstract
The growing list of available therapies for patients with multiple myeloma has resulted in tremendously high response rates and prolonged survival. However, the cure remains elusive. A continued effort at developing strategies to utilize all available treatment modalities in the most effective manner is needed. Allogeneic hematopoietic cell transplantation (allo-HCT) is a robust platform, associated with high response rates, and provides a unique foundation on which immune therapies and novel agents can be employed to improve clinical outcomes. Patients with high-risk myeloma and those relapsing after novel agent-based therapies or early after an autologous HCT should be considered for allo-HCT, ideally in a clinical trial setting. Results from several ongoing studies are expected to provide important information that will help determine the place of allo-HCT in the myeloma treatment algorithm.